ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs in solid tumors through Clinical Development September 10, 2024
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) show strong favorable OS trend versus osimertinib in EGFR-mutated advanced lung cancer September 10, 2024
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody September 10, 2024
IDMC recommends continuing Ph 3 trial (IOB-013/KN-D18) of IO102-IO103 following a per-protocol interim analysis September 10, 2024
Ivonescimab Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab in 1L PD-L1+ve Advanced NSCLC patients in China September 10, 2024
Fast Track Designation Granted for VMT01 for the Diagnosis & Treatment of MC1R-Positive Melanoma September 10, 2024
FDA approves BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or IV administration September 10, 2024
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors September 10, 2024
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA September 10, 2024
Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer September 10, 2024
Novartis begins construction of two new radioligand therapy facilities in the US, expanding RLT manufacturing and supply network September 10, 2024
GBM program of INB-200 and INB-400 to be suspended; AML program of INB-100 to be prioritized September 10, 2024
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Ph 1b Trial in DLBCL announced September 10, 2024
New Case Study Demonstrating Reactivation of P-BCMA-101 CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma Presented September 10, 2024
New clinical data from ongoing Ph 1/2 VBP101 study of patients with R/R AML receiving trem-cel followed by Mylotarg announced September 10, 2024
Ifinatamab Deruxtecan Continues to Demonstrate Promising ORR in Patients with Extensive-Stage SCLC in IDeate-Lung01 Ph 2 Trial September 10, 2024
Novel computational pathology-based TROP2 biomarker for Dato-DXd was predictive of clinical outcomes in patients with NSCLC in TROPION-Lung01 September 10, 2024
FDA Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in R/R AML September 10, 2024
FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma September 10, 2024
Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma September 10, 2024
